Breast cancer

HEROES

De-escalation of medical treatments in HER2-positive metastatic breast cancer in case of long-term persistent response and undetectable minimal residual disease assessed by circulating tumor DNA.

Open at Paris since : 07/05/2025
Open at Saint-Cloud since : 07/05/2025
Target : Adult
Phase : Phase II

Trial description

To assess the feasibility of therapeutic de-escalation in HER2-positive metastatic breast cancer patients whose disease is controlled after 2 years of maintenance anti-HER2 targeted therapy and who have a negative circulating tumor DNA (ctDNA) test.

Url of the trial

Main investigator

DIANA BELLO ROUFAI

Médecin

Contact